All In Biotech

Drug Trial Radar · NCT04762069

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

252

Actual

Start

May 18, 2021

Primary completion

Apr 27, 2026

Study completion Jul 15, 2026

Sponsor

Lead sponsor
CNS Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials
First posted
Feb 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.

Conditions

  • Glioblastoma Multiforme, Adult

Interventions

  • BerubicinDrug

    Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.

  • LomustineDrug

    Lomustine is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as an "alkylating agent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Through study completion an average of 4 years.

Locations

48 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Arkansas

    Little Rock, Arkansas

  • Southern California Permanente Medical Group

    Los Angeles, California

  • University of California Irvine

    Orange, California

  • University of Califonia San Diego Moores Cancer Center

    San Diego, California

  • University of California San Francisco

    San Francisco, California

  • Saint John's Cancer Institute at Providence Saint John's Health Center

    Santa Monica, California

  • HCA Healthcare Research Institute

    Englewood, Colorado

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Baptist Miami

    Miami, Florida

  • Piedmont Healthcare

    Atlanta, Georgia

  • Rush University Cancer Center

    Chicago, Illinois

  • University of Kentucky

    Lexington, Kentucky

  • Tulane Cancer Center Clinic

    New Orleans, Louisiana

  • Tufts Medical Center

    Boston, Massachusetts

  • UMass (ACC) - Hollings Cancer Center (HCC)

    Worcester, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Hackensack Meridian Health

    Hackensack, New Jersey

  • Rutgers University

    Piscataway, New Jersey

  • Atlantic Healthcare

    Summit, New Jersey

  • Roswell Park Cancer Center

    Buffalo, New York

  • Duke University School of Medicine

    Durham, North Carolina

  • Ohio State University

    Columbus, Ohio

  • Providence Health

    Portland, Oregon

  • Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Texas Oncology PA

    Austin, Texas

  • Baylor Research Institute

    Dallas, Texas

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • Huntsman Cancer Center

    Salt Lake City, Utah

  • Swedish Medical Center

    Seattle, Washington

  • University of Wisconsin Hospital and Clinics

    Madison, Wisconsin

  • Hopital Pierre Wertheimer

    Lyon, France

  • Hopital de La Timone

    Marseille, France

  • Institut de Recherche en Cancerologie de Montpellier

    Montpellier, France

  • Hopital Pitie-Salpetriere

    Paris, France

  • Institut de Cancerologie de l'Ouest

    Saint-Herblain, France

  • nstitut Universitaire du Cancer de Toulouse-

    Toulouse, France

  • Institut de Cancerologie Gustave-Roussy

    Villejuif, France

  • Servizio Sanitario Regionale Emilia-Romagna - Azienda USL di Bologna - Ospedale Bellaria

    Bologna, Italy

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.